Literature DB >> 2505171

Routine cholecystectomy in the morbidly obese.

M J Mooney, P L Carter.   

Abstract

Proven disease is generally considered a sound indication for cholecystectomy. However, incidental removal of a gallbladder with unproven pathology is controversial. The morbidly obese, however, constitute a group at especially high risk for the development of gallbladder disease, with possible greater risk immediately after weight reduction procedures. In our series of 51 consecutive patients undergoing vertical banded gastroplasty (VBG), the gallbladder was routinely removed regardless of symptomatology or results of a preoperative workup. Two patients declined cholecystectomy. Twelve patients (24.4%) had undergone cholecystectomy for symptomatic stones prior to their VBG. Of the remaining 37 subjects, there was a 73% overall incidence of disease: 11 (29.7%) had cholelithiasis, 11 (29.7%) had cholesterolosis alone, three (8.1%) had chronic cholecystitis with cholesterolosis, and two (5.4%) had chronic cholecystitis alone; only 10 (27%) had normal findings. These results, when added to evidence demonstrating a high incidence of postoperative gallbladder disease in those not receiving cholecystectomy, suggest that routine cholecystectomy be considered in all morbidly obese patients undergoing VBG or similar procedures.

Entities:  

Mesh:

Year:  1989        PMID: 2505171

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

Review 1.  Cholecystectomy for biliary dyskinesia: how did we get there?

Authors:  Klaus Bielefeldt; Shreyas Saligram; Susan L Zickmund; Anwar Dudekula; Mojtaba Olyaee; Dhiraj Yadav
Journal:  Dig Dis Sci       Date:  2014-09-06       Impact factor: 3.199

2.  Histologic findings of gallbladder mucosa in 87 patients with morbid obesity without gallstones compared to 87 control subjects.

Authors:  Attila Csendes; Patricio Burdiles; Gladys Smok; Paula Csendes; Ana Burgos; Mauricio Recio
Journal:  J Gastrointest Surg       Date:  2003 May-Jun       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.